The NLRP3 inflammasome: an emerging therapeutic target for chronic pain.

Abstract

Chronic pain affects the life quality of the suffering patients and posts heavy problems to the health care system. Conventional medications are usually insufficient for chronic pain management and oftentimes results in many adverse effects. The NLRP3 inflammasome controls the processing of proinflammatory cytokine interleukin 1β (IL-1β) and is implicated in a variety of disease conditions. Recently, growing number of evidence suggests that NLRP3 inflammasome is dysregulated under chronic pain condition and contributes to pathogenesis of chronic pain. This review provides an up-to-date summary of the recent findings of the involvement of NLRP3 inflammasome in chronic pain and discussed the expression and regulation of NLRP3 inflammasome-related signaling components in chronic pain conditions. This review also summarized the successful therapeutic approaches that target against NLRP3 inflammasome for chronic pain treatment.

• Authors: Ruixiang Chen, Chengyu Yin, Jianqiao Fang, Boyi Liu
• Journal: Journal of neuroinflammation (J Neuroinflammation) Vol. 18 Issue 1 Pg. 84 (Mar 30 2021) ISSN: 1742-2094 [Electronic] England
• PMID: 33785039 (Publication Type: Journal Article, Review)

Chemical References

• Furans
• Indenes
• NLR Family, Pyrin Domain-Containing 3 Protein
• NLRP3 protein, human
• Sulfonamides
• N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide

Topics

• Animals
• Chronic Pain (drug therapy, metabolism)
• Drug Delivery Systems (methods, trends)
• Furans (administration & dosage)
• Humans
• Indenes (administration & dosage)
• NLR Family, Pyrin Domain-Containing 3 Protein (antagonists & inhibitors, metabolism)
• Sulfonamides (administration & dosage)